Fact-checked by Grok 2 weeks ago

Pervasive developmental disorder

Pervasive developmental disorders (PDDs) constituted a diagnostic category in the DSM-IV, referring to a spectrum of neurodevelopmental conditions defined by severe, pervasive impairments in reciprocal social interactions, verbal and skills, and the presence of stereotyped behaviors, interests, or activities, with onset typically before age three. This category encompassed five subtypes: autistic disorder, Asperger's disorder, pervasive developmental disorder (PDD-NOS), Rett's disorder, and . Empirical evidence from twin and family studies underscores a strong genetic for these disorders, with estimates exceeding 80% in many cases, alongside neurobiological markers such as atypical brain connectivity and early developmental disruptions, though environmental factors play a minor, non-causal role in most instances. In the (2013), the PDD framework was replaced by to adopt a dimensional model emphasizing symptom severity across a continuum, as subtype distinctions like Asperger's showed limited clinical utility and poor diagnostic stability in longitudinal studies. Over 90% of individuals previously diagnosed with PDD subtypes retained an diagnosis under criteria, reflecting empirical validation of the spectrum approach while preserving recognition of high-functioning presentations formerly labeled Asperger's or PDD-NOS. Core defining characteristics include deficits in social-emotional reciprocity and nonverbal communicative behaviors, alongside insistence on sameness and sensory sensitivities, with Rett's disorder distinguished by its specific genetic basis in MECP2 and regressive course. Prognosis varies widely, with early intensive behavioral interventions yielding measurable gains in adaptive functioning for some, though lifelong challenges in persist absent robust causal interventions targeting underlying neural mechanisms. Controversies surrounding the shift include concerns over diminished specificity for milder forms, potentially impacting access to tailored supports, though data affirm improved reliability without substantial loss of case identification.

Definition and Overview

Core Definition

Pervasive developmental disorders (PDDs) constituted a diagnostic category in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV, published ), encompassing neurodevelopmental conditions marked by severe and widespread impairments in reciprocal social interactions, verbal and skills, and the presence of stereotyped behaviors, interests, or activities. This category included five specific disorders: autistic disorder, Asperger's disorder, Rett's disorder, , and pervasive developmental disorder not otherwise specified (PDD-NOS). These conditions typically manifest in , with delays or atypical development evident by age 3 in core domains, distinguishing them from other developmental delays by their broad, penetrating impact across multiple functional areas rather than isolated deficits. The core diagnostic feature of PDDs involved qualitative impairments in social reciprocity, such as reduced , lack of shared enjoyment, or failure to develop peer relationships, alongside communication challenges like delayed , , or pragmatic deficits in conversation. Repetitive and restricted patterns of behavior, including motor stereotypies, insistence on sameness, or circumscribed interests, further defined the , often leading to functional limitations in adaptive skills. Unlike narrower developmental disorders, PDDs were deemed "pervasive" due to their multifaceted , potentially involving genetic, neurological, and environmental factors, though causal mechanisms remain incompletely understood and vary by subtype— for instance, Rett's disorder linked to MECP2 gene mutations identifiable via . Prevalence estimates for PDDs under DSM-IV criteria ranged from 2 to 6 per 1,000 children, with PDD-NOS comprising 40% of cases due to its residual nature for subthreshold presentations. Empirical studies emphasized early identification through standardized tools like the (ADOS), underscoring that untreated PDDs correlate with lifelong challenges in independence and , though outcomes improve with targeted behavioral interventions. This framework prioritized observable behavioral criteria over speculative theories, reflecting a shift toward empirical validation in psychiatric since the DSM-III introduction of PDDs in 1980.

Distinction from Autism Spectrum Disorder

Prior to the , published in 2013 by the , pervasive developmental disorders (PDDs) encompassed a heterogeneous group of neurodevelopmental conditions defined by significant impairments in social interaction, communication, and the presence of restricted or repetitive behaviors, including autistic disorder, Asperger's disorder, PDD (PDD-NOS), , and . Autistic disorder specifically required onset before age 3 with marked deficits meeting strict thresholds, whereas PDD-NOS applied to cases with atypical or subthreshold presentations that did not fully satisfy criteria for autistic disorder or Asperger's but still evidenced pervasive developmental delays. In contrast, autism spectrum disorder (ASD), introduced in the DSM-5, consolidates these PDD subtypes—excluding Rett syndrome, which is now classified as a distinct genetic disorder—into a unified spectrum diagnosis characterized by persistent deficits in social communication and interaction alongside restricted, repetitive patterns of behavior, interests, or activities, with severity levels (1-3) to denote support needs. This shift reflects empirical evidence from longitudinal studies indicating that PDD categories overlapped substantially in symptom profiles and outcomes, with 99% of prior autistic disorder cases and most Asperger's and PDD-NOS cases meeting DSM-5 ASD criteria. PDD-NOS, previously the most common PDD subtype comprising about 47% of diagnoses, often represented milder or "atypical" autism-like features without full repetitive behavior requirements, but under DSM-5, such cases are subsumed into ASD unless repetitive behaviors are absent, potentially leading to a separate social (pragmatic) communication disorder diagnosis. The nosological distinction underscores a move from categorical silos to a dimensional model, driven by factor-analytic research showing symptom continuity rather than discrete boundaries, though critics argue this may obscure prognostic differences, as PDD-NOS historically correlated with better long-term adaptation than classic autism. Prevalence studies post-DSM-5 indicate that ASD plus social communication disorder rates approximate prior PDD totals (around 2.64%), suggesting the change maintains diagnostic stability while enhancing clinical utility through specifiers for intellectual impairment, language status, and associated conditions. This evolution prioritizes observable behavioral criteria over presumed etiologies, aligning with causal realism in recognizing autism's multifactorial origins, including genetic and environmental factors, without implying uniform pathology across the spectrum.

Historical Development

Early Conceptualizations

The concept of pervasive developmental disorders originated from early clinical observations of children exhibiting profound, widespread impairments in social interaction, communication, and , distinct from psychotic conditions like . In 1943, described "early infantile " based on 11 cases, highlighting "autistic disturbances of affective contact" characterized by extreme aloofness from human contact, delayed or deviant language (such as and pronominal reversal), and rigid insistence on sameness in routines and environments, which collectively disrupted multiple developmental domains from infancy. These features were seen as innate and pervasive, affecting emotional reciprocity and symbolic play, rather than isolated cognitive deficits. Independently, in 1944, reported on children with "autistic psychopathy," noting similar social detachment, pedantic speech, and circumscribed interests, but with relatively intact language and , suggesting a spectrum of severity in these pervasive traits that persisted into adulthood. Early post-war views often conflated these presentations with , as in Lauretta Bender's 1947 descriptions of schizophrenic syndromes in young children involving withdrawal and stereotypies, or Bruno Bettelheim's 1967 psychogenic theories attributing autism to parental emotional deprivation ("refrigerator mothers"). Such conceptualizations emphasized environmental causation and symptomatic overlap with , leading to its classification under in the DSM-II (1968). By the 1970s, empirical research shifted toward a neurodevelopmental framework, with Michael Rutter's studies (, ) differentiating through early onset (before 30 months), absence of delusions or hallucinations, and familial patterns, unlike schizophrenia's later emergence. Rutter proposed diagnostic criteria encompassing the triad of reciprocal social impairment, communication deviance, and repetitive behaviors or interests, framing as a cognitive and with pervasive effects across and , independent of IQ. This triadic model underscored the "pervasive" nature—impairments infiltrating broad developmental processes—paving the way for formal categorization beyond schizophrenic labels.

Evolution in Diagnostic Manuals

The category of pervasive developmental disorders (PDD) was introduced in the Diagnostic and Statistical Manual of Mental Disorders, Third Edition (DSM-III), published by the in 1980, as a novel diagnostic class to classify severe, early-onset impairments across multiple developmental domains, including social reciprocity, language, and symbolic play, thereby differentiating these from narrower or psychotic conditions. The DSM-III specified three subtypes: infantile (onset before 30 months with marked social withdrawal), childhood-onset pervasive developmental disorder (onset between 30 and 60 months), and residual type (active phase criteria no longer met but with ongoing impairments). The DSM-III-R (1987) revised these criteria to emphasize behavioral manifestations over presumed etiology, renaming infantile autism as autistic disorder while retaining requirements for onset before 36 months and pervasive deficits; it consolidated the other subtypes into a single residual category and introduced pervasive developmental disorder not otherwise specified (PDD-NOS) for cases with atypical features or partial symptom clusters that impaired functioning but did not fully align with autistic disorder. These adjustments aimed to enhance diagnostic specificity amid emerging evidence of heterogeneous presentations, though field trials revealed ongoing challenges in for borderline cases. Subsequent iterations in the DSM-IV (1994) and DSM-IV-TR (2000) expanded PDD to five discrete disorders—autistic disorder, Asperger's disorder (no significant ), Rett's disorder (genetic-specific regression), (late-onset regression), and PDD-NOS—based on variations in onset age, intellectual functioning, and language development, supported by epidemiological data showing distinct prevalence rates (e.g., autistic disorder at approximately 4-6 per 1,000 children). Parallel evolution occurred in the , Tenth Revision (ICD-10, effective 1994), which codified PDD under block F84 with analogous subtypes, facilitating global consistency but highlighting cross-manual discrepancies in criteria thresholds. The (2013) dismantled the PDD framework entirely, subsuming all prior subtypes into a unified disorder () diagnosis defined by two core domains—social-communication deficits and restricted/repetitive behaviors—with severity specifiers and allowances for co-occurring or language impairment, justified by factor-analytic studies demonstrating dimensional rather than categorical distinctions and genetic overlap across former subtypes. This shift, echoed in the (effective 2022), prioritized empirical validity from and research (e.g., shared polygenic risk scores exceeding 80% across spectrum presentations) over subtype granularity, though critics noted potential loss of specificity for high-functioning cases previously classified as Asperger's or PDD-NOS.

Diagnostic Criteria and Classification

Pre-DSM-5 Criteria

In the DSM-IV (1994) and its text revision DSM-IV-TR (2000), pervasive developmental disorders (PDDs) were defined as a category of neurodevelopmental conditions involving severe, pervasive delays or deviant patterns in social interaction, communication, and the of representational or symbolic play activities, often accompanied by restricted, repetitive behaviors or interests, with onset typically in infancy or . The diagnostic framework required evidence of qualitative impairments across these domains, distinguishing PDDs from other developmental delays or psychotic disorders, and emphasized that symptoms must cause clinically significant functional impairment without being better explained by alone or environmental deprivation. The DSM-IV classified five specific disorders under PDDs, each with tailored criteria but sharing core features of early developmental deviance:
  • Autistic Disorder: Required onset of delays before age 3 in at least one of social interaction, , or symbolic play, plus a total of six or more symptoms from three domains—qualitative in social interaction (e.g., marked lack of awareness of others' feelings, failure to develop peer relationships); qualitative in communication (e.g., delay in , stereotyped idioms, lack of varied make-believe play); and restricted, repetitive, stereotyped behaviors (e.g., encompassing preoccupation, inflexible adherence to routines, repetitive motor mannerisms). At least two symptoms from social interaction, one from communication, and one from behaviors were mandated.
  • Rett's Disorder: Characterized by normal prenatal and perinatal development followed by apparently normal psychomotor development through the first 5 months, then specific deficits including deceleration of head growth, loss of previously acquired purposeful hand skills, loss of , poorly coordinated , and stereotyped hand-wringing movements, primarily affecting females due to its association with MECP2 gene mutations.
  • Childhood Disintegrative Disorder: Involved apparently normal development for at least the first 2 years, followed by clinically significant loss of previously acquired skills before age 10 in at least two areas (e.g., , , bowel/ control, play, motor skills), plus abnormalities in at least two of the three autistic domains: social interaction, communication, and restricted behaviors.
  • Asperger's Disorder: Featured severe and sustained impairment in social interaction and restricted, repetitive patterns of similar to , but without clinically significant delays in , , self-help skills, or (though curiosity about the environment in infancy was noted as potentially impaired). Diagnosis excluded history of pervasive .
  • Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS): Applied when there was severe and pervasive impairment in reciprocal social interaction and/or verbal/ skills, or presence of stereotyped behaviors, but full criteria for autistic disorder, Asperger's, Rett's, or were not met; the disturbance had to cause significant impairment and not align with or other personality disorders. This residual category captured subthreshold presentations, such as atypical or milder forms with later onset.
These criteria relied on clinical , developmental , and standardized assessments, with varying by disorder (higher for autistic disorder than PDD-NOS), and required exclusion of alternative explanations like sensory impairments or environmental factors. The framework allowed for comorbid diagnoses, such as , but prioritized behavioral phenomenology over etiology.

DSM-5 Consolidation and Implications

In the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), published by the American Psychiatric Association in May 2013, the previous DSM-IV-TR categories of pervasive developmental disorders—including autistic disorder, Asperger's disorder, pervasive developmental disorder not otherwise specified (PDD-NOS), and childhood disintegrative disorder—were merged into a single diagnostic entity termed autism spectrum disorder (ASD). Rett's disorder was excluded from this consolidation and reclassified as a distinct neurological condition due to its identifiable genetic etiology involving MECP2 mutations. The DSM-5 criteria for ASD require persistent deficits in social communication and interaction across multiple contexts, alongside restricted, repetitive patterns of behavior, interests, or activities, with symptoms present from early development and causing clinically significant impairment. This merger aimed to address empirical shortcomings in the DSM-IV framework, where subcategories often failed to align with genetic, neurobiological, or prognostic realities, leading to inconsistent application and diagnostic —such as shifting from PDD-NOS to Asperger's based on preference rather than distinct etiologies. Field trials preceding demonstrated that the unified criteria maintained high sensitivity (capturing 91-97% of prior DSM-IV PDD cases) while enhancing specificity by eliminating arbitrary distinctions like the presence of , which studies showed did not reliably differentiate outcomes or underlying causes. Proponents argued the change better reflects autism's dimensional spectrum, supported by factor analyses of symptom data indicating continuous rather than categorical variation, thereby facilitating more homogeneous research cohorts and targeted interventions. Clinically, the DSM-5 introduced severity levels (1-3) based on required support in social communication and repetitive behaviors, alongside specifiers for co-occurring intellectual impairment, language status, and known medical/genetic conditions, enabling nuanced profiling without rigid subtypes. However, reevaluation studies indicate that 10-40% of individuals previously diagnosed with PDD-NOS or Asperger's—particularly those with average or above-average IQ and fewer repetitive behaviors—may not meet DSM-5 ASD thresholds, potentially reducing prevalence estimates by up to 30% in community samples and raising concerns over access to services tied to ASD eligibility. Conversely, the framework grandfathered prior diagnoses, minimizing immediate disruptions, and introduced social (pragmatic) communication disorder as an alternative for social deficits absent repetitive behaviors, though its validity remains debated due to limited longitudinal data distinguishing it from milder ASD. For research, the promises improved replicability by reducing diagnostic heterogeneity, as evidenced by post-DSM-5 studies showing tighter genotype-phenotype correlations in large cohorts, though critics note potential loss of granularity for subgroups with divergent trajectories, such as high-functioning individuals who benefited from Asperger's-specific supports. Overall, while driven by psychometric and favoring a spectrum model, the shift underscores ongoing tensions between categorical diagnostics and empirical continua, with real-world implications monitored through systems like the CDC's and Developmental Disabilities Monitoring Network, which reported stable post-2013 despite criteria changes.

Signs and Symptoms

Social and Communication Impairments

Individuals with pervasive developmental disorders (PDDs) exhibit qualitative impairments in social interaction, characterized by deficits in multiple domains including and reciprocity. These impairments often manifest as reduced eye-to-eye gaze, limited use of facial expressions, body postures, or gestures to initiate or regulate social interactions, and a to develop age-appropriate peer relationships. Lack of spontaneous sharing of enjoyment, interests, or achievements with others, along with absence of social or emotional reciprocity—such as adjusting behavior based on others' emotions or engaging in —is consistently observed across PDD subtypes like autistic disorder and PDD (PDD-NOS). Communication deficits in PDDs involve both verbal and nonverbal elements, with delays or absence of development in many cases, particularly prior to age 3. Affected individuals frequently demonstrate inability to initiate or sustain conversations, stereotyped or repetitive use of (e.g., or idiosyncratic phrasing), and impoverished imaginative or symbolic play. Pragmatic impairments are prominent, including difficulties in using communication for social purposes, adapting speech to contextual demands, and adhering to conversational rules such as or rephrasing for clarity. In PDD-NOS, these communication issues may present as subthreshold symptoms, with preserved basic milestones but persistent challenges in reciprocal or functional use. The interplay between social and communication impairments underscores their pervasive nature in PDDs, where social withdrawal, inappropriate comments, or atypical physical interactions (e.g., uninvited touching) often stem from deficits in interpreting or expressing intent. Empirical studies confirm these features as core diagnostic elements under DSM-IV criteria, distinguishing PDDs from other developmental delays through their qualitative rather than merely quantitative deviations. Variability exists; for instance, individuals with Asperger's disorder—classified under PDDs—typically lack early delays but show comparable social reciprocity deficits and pragmatic impairments. These symptoms, evident from , contribute to clinically significant functional limitations in social settings.

Restricted and Repetitive Behaviors

Restricted and repetitive behaviors (RRBs) constitute one of the two diagnostic domains for pervasive developmental disorders (PDDs), alongside and communication impairments, as outlined in pre-DSM-5 classifications such as DSM-IV-TR, where they were required for diagnoses including autistic disorder and PDD (PDD-NOS). These behaviors encompass a range of repetitive motor actions, rigid adherence to routines, intense preoccupations with specific interests, and atypical sensory responses, often emerging in and persisting into adulthood. In children with or PDD-NOS, RRBs occur more frequently and with greater severity compared to those with developmental delays without PDD, with studies of toddlers and preschoolers showing elevated rates of behaviors such as hand flapping, object spinning, and insistence on sameness. RRBs can be categorized into lower-order (e.g., stereotyped motor movements like rocking or ) and higher-order subtypes (e.g., ritualistic behaviors and circumscribed interests), with the former often more prominent in younger children and the latter associated with cognitive rigidity. Specific manifestations include repetitive use of objects (e.g., lining up toys), inflexible routines that provoke distress when disrupted, and fixated interests disproportionate to age-typical hobbies, such as an intense focus on schedules. Sensory-related RRBs, like to textures or seeking intense proprioceptive input through spinning, also feature prominently, contributing to diagnostic specificity. Longitudinal research indicates developmental trajectories where RRBs may decrease in frequency with age in some individuals but remain stable or intensify in others, particularly higher-order forms linked to anxiety and reduced behavioral flexibility. These behaviors serve potential adaptive functions, such as sensory regulation or anxiety mitigation, though they frequently impair daily functioning by limiting adaptability and . In PDD cohorts, RRBs correlate with poorer adaptive outcomes and co-occurring psychiatric symptoms, underscoring their role as barriers to learning and independence. Early identification through standardized tools like the Repetitive Behavior Scale-Revised reveals their predictive value for , with higher severity in versus PDD-NOS reflecting spectrum heterogeneity. Empirical data from large-scale surveillance, such as the CDC's Autism and Developmental Disabilities Monitoring , affirm RRBs as invariant across PDD presentations, essential for distinguishing from other developmental conditions.

Variability in Presentation

Presentations of pervasive developmental s (PDDs) under DSM-IV criteria exhibited substantial heterogeneity, encompassing differences in symptom severity, age of onset, and specific impairments across subtypes such as autistic , Asperger's , and PDD (PDD-NOS). Autistic typically involved severe, early-onset deficits in reciprocal interaction, communication delays, and restricted repetitive behaviors, often accompanied by in approximately 70% of cases. In contrast, Asperger's featured preserved or advanced verbal abilities without significant early language delays, alongside reciprocity challenges and repetitive interests, with individuals generally demonstrating average or above-average intelligence. PDD-NOS, the most common subtype, captured atypical or subthreshold manifestations that failed to meet full criteria for other PDDs, resulting in milder or uneven symptom profiles, such as isolated impairments without pronounced repetitive behaviors. Within subtypes, variability further manifested in the degree of core domain involvement, with some individuals showing predominant social withdrawal and others emphasizing communication peculiarities or behavioral rigidity. For instance, children with PDD-NOS often displayed stronger adaptive and cognitive functioning compared to those with autistic disorder, including better performance in daily living skills and fewer severe repetitive patterns, though outcomes varied widely with age and . High-functioning presentations across PDDs correlated with gradients in symptom intensity, where subtle misinterpretation predominated over gross developmental delays, influenced by factors like genetic loading and environmental modifiers. Comorbid conditions amplified presentation diversity; for example, overlapping attention-deficit/hyperactivity disorder (ADHD) symptoms in PDD subtypes intensified oppositional behaviors or inattention, particularly in combined ADHD presentations, altering the clinical picture toward greater behavioral dysregulation. Gender differences contributed to heterogeneity, with males overrepresented (ratio approximately 4:1) and females potentially exhibiting less overt repetitive behaviors but more internalizing issues, leading to underdiagnosis in milder cases. Overall, this spectrum-like variability underscored PDDs as a heterogeneous group, challenging uniform diagnostic thresholds and highlighting the need for individualized assessment.

Etiology and Risk Factors

Genetic Contributions

Twin studies have established high for pervasive developmental disorders (PDDs), particularly autism spectrum disorder (), a core component of the PDD category. Monozygotic twin concordance rates range from 70% to 90%, compared to 6% to 10% in dizygotic twins, yielding estimates of approximately 80% to 90%. These findings indicate that genetic factors explain the majority of liability, with shared environmental influences accounting for a smaller portion, around 55% in some models. Genetic architecture involves a combination of common polygenic variants, rare inherited mutations, and mutations. Polygenic risk scores (PRS) derived from genome-wide association studies capture cumulative effects of common variants, associating with traits and explaining less than 1% of phenotypic variance, though they correlate with subclinical features like reduced neurite density or facial emotion recognition deficits in the general population. Rare variants, including copy number variations and loss-of-function mutations, contribute significantly, with over 100 genes implicated across synaptic, , and pathways. mutations, often disruptive and occurring in genes like SCN2A, CHD8, and ADNP, are enriched in (sporadic) cases, accounting for 52% to 67% of risk in low-risk families but less in multiplex families with inherited transmission. This heterogeneity underscores that no single gene causes PDDs; instead, risk arises from combinatorial effects, with events disproportionately impacting and motor skills. Genetic contributions vary by family history, with inherited polygenic and rare variants more prominent in high-risk pedigrees. Comprehensive sequencing reveals that while high-confidence genes number around 100, the full involves thousands of loci, emphasizing the need for integrative models over deterministic views.

Environmental and Prenatal Factors

Advanced parental age at conception is a well-established prenatal for autism spectrum disorder (), the primary condition encompassed by pervasive developmental disorders. Meta-analyses indicate that children born to fathers over 45 years old face approximately 1.5- to 2-fold increased odds of compared to those with fathers under 30, with risks escalating nonlinearly and potentially linked to de novo mutations in . Maternal age over 30 similarly elevates risk, with odds ratios around 1.3-1.5, though paternal age effects are often stronger and independent of maternal age. These associations hold across large cohort studies controlling for confounders like . Maternal health conditions during , including , , and infections, show consistent associations with elevated risk. Pre-pregnancy maternal correlates with 1.3- to 2-fold higher odds, potentially via inflammatory pathways or metabolic disruptions affecting fetal neurodevelopment. and maternal infections (e.g., or ) likewise increase risk by 1.2- to 1.5-fold in systematic reviews, though causality remains inferred from observational data rather than randomized evidence. Prenatal exposure to certain medications, notably valproic acid for or mood stabilization, substantially heightens likelihood, with offspring facing 5- to 10-fold increased risk, prompting clinical guidelines to avoid it in pregnancy when possible. Environmental exposures, including and toxins, exhibit weaker, often correlational links to . Prenatal or early postnatal exposure to fine particulate matter (PM2.5) or (NO2) is associated with modest risk increases (odds ratios 1.1-1.4 per increment), particularly in urban cohorts, but studies highlight potential by factors like traffic proximity or socioeconomic variables. Similarly, prenatal , pesticides, and (e.g., mercury, lead) show positive associations in meta-analyses, yet effect sizes are small and replication inconsistent, underscoring challenges in isolating causation amid genetic predispositions. Overall, while these factors may interact with high (estimated 70-90%) to modulate risk, no single environmental agent explains substantial variance, and preventive claims require further causal validation.

Evidence Against Common Misconceptions

A common misconception posits that , particularly the or thimerosal-containing ones, cause pervasive developmental disorders such as , a core component of the former PDD category. This claim originated from a 1998 study by , which was retracted due to methodological flaws and undeclared conflicts of interest, including financial incentives tied to litigation against vaccine manufacturers. Subsequent large-scale epidemiological studies, including a of over 1.2 million children, found no association between MMR vaccination, thimerosal exposure, or vaccine schedules and ASD risk. The Centers for Disease Control and Prevention (CDC) has corroborated this through analyses of U.S. vaccination data, showing ASD onset timing unrelated to immunization. Another persistent myth attributes PDDs to inadequate parenting, exemplified by the popularized in the mid-20th century by , which blamed emotionally distant mothers for children's withdrawal and developmental delays. This psychogenic view lacked empirical support and ignored neurological evidence; brain imaging and postmortem studies reveal structural and functional differences in brains, such as altered in social processing regions, present from early infancy. Twin studies demonstrate low concordance with across siblings, while rejecting the theory spurred biological research confirming ASD's neurodevelopmental origins independent of family dynamics. Claims that environmental factors alone, such as prenatal medications or modern lifestyle exposures, fully explain PDDs overlook robust genetic evidence. estimates for range from 64% to 91% based on twin and family studies across populations, indicating genetic variants—over 100 identified, including mutations in genes like SHANK3 and CHD8—account for the majority of liability. While prenatal factors like advanced parental age or maternal infections modestly elevate ( ratios 1.3-1.5), they interact with polygenic backgrounds rather than acting in isolation, as evidenced by population cohorts from five countries showing 80% after controlling for shared environments. Misattributing to singular non-genetic triggers ignores this multifactorial model, where rare environmental effects explain less than 20% of variance.

Treatment and Management

Behavioral and Educational Interventions

Behavioral interventions for pervasive developmental disorders (PDDs), now encompassed under autism spectrum disorder (ASD) in , primarily draw from (ABA), which uses principles of such as positive reinforcement and prompting to address core deficits in social communication, adaptive skills, and repetitive behaviors. -based programs, including and naturalistic teaching strategies, have demonstrated moderate to large effect sizes in meta-analyses, with improvements in intellectual functioning (e.g., IQ gains of 15-20 points), , and daily living skills observed in children receiving 20-40 hours weekly. Early intensive behavioral intervention (EIBI), a form of ABA initiated before age 3, yields sustained benefits in randomized controlled trials, including reduced symptom severity and enhanced social engagement persisting into school age, though outcomes vary by intervention intensity and child baseline functioning. Educational interventions complement behavioral approaches by structuring learning environments to accommodate sensory sensitivities and promote independence, with evidence supporting practices like visual supports, , and functional behavior assessments in school settings. The Treatment and Education of Autistic and Related Communication-Handicapped Children (TEACCH) emphasizes individualized, structured using physical and visual cues to improve task completion and , showing small positive effects on perceptual-motor and verbal abilities in meta-analyses, though randomized studies are limited and effects on social functioning remain inconsistent. Comprehensive school-based models integrating principles with peer-mediated strategies and small-group instruction have been identified as evidence-based, leading to gains in academic engagement and for youth with PDDs, particularly when implemented early and with fidelity to protocols. Long-term efficacy depends on factors such as dosage (e.g., at least 15-25 hours weekly for EIBI) and parental involvement, with systematic reviews indicating that higher-intensity correlates with better adaptive outcomes but diminishing returns beyond 40 hours. While developmental relationship-based interventions like /Floortime show preliminary benefits in emotional regulation through child-led play, they lack the robust randomized trial support of ABA and are often adjunctive rather than primary. Overall, behavioral and educational interventions grounded in empirical data from controlled trials outperform eclectic or non-structured approaches, with meta-analytic evidence underscoring the need for individualized plans to mitigate risks of stagnation in untreated PDD symptoms.

Pharmacological Options

No medications have been approved or demonstrated to treat the core social, communication, or behavioral deficits associated with pervasive developmental disorders, now largely encompassed under autism spectrum disorder (ASD) in contemporary classifications. Pharmacological interventions primarily target co-occurring symptoms such as irritability, aggression, hyperactivity, or anxiety, with evidence derived from randomized controlled trials (RCTs) and meta-analyses showing variable efficacy and notable risks. Guidelines emphasize that drugs should be used adjunctively to behavioral therapies, with careful monitoring due to heightened sensitivity in this population. Risperidone and aripiprazole are the only agents approved by the U.S. (FDA) for managing in children and adolescents with . Risperidone received approval in 2006 for ages 5-16 years, based on two 8-week RCTs involving 101 and 98 participants, respectively, which demonstrated significant reductions in scores on the Aberrant Behavior Checklist () subscale compared to (effect sizes 0.9-1.2). Aripiprazole was approved in 2009 for ages 6-17 years, supported by two fixed-dose RCTs (190 and 218 participants) showing score reductions of 8-13 points versus 5-7 for . Both antipsychotics also yield secondary benefits in aggression, self-injurious behavior, and tantrums, but long-term use (beyond 6-12 months) requires reassessment due to risks including (up to 4-5 kg in 6 months), hyperprolactinemia, , and metabolic disturbances like . Head-to-head comparisons indicate comparable efficacy, though aripiprazole may have a slightly better tolerability profile for . Selective serotonin reuptake inhibitors (SSRIs), such as or , have been investigated for restricted and repetitive behaviors (RRBs), hypothesizing serotonin dysregulation, but systematic reviews and meta-analyses consistently report limited or no superiority over . A 2020 meta-analysis of five RCTs (n=271) found no significant ABC-compulsive subscale improvements with SSRIs, with effect sizes near zero. An earlier 2009 multicenter RCT of (n=149 children) confirmed inefficacy for RRBs alongside increased adverse events like and . While some open-label studies suggest modest anxiety reductions, routine use is not recommended due to activation risks and lack of robust evidence. For comorbid attention-deficit/hyperactivity disorder (ADHD) symptoms, psychostimulants like show moderate efficacy in improving inattention and hyperactivity, with RCTs reporting response rates of 50-70% in cohorts, though lower than in idiopathic ADHD. A 2019 review noted stimulants' benefits in combined ASD-ADHD presentations but highlighted elevated risks of emotional exacerbation or irritability in up to 20-30% of cases, often necessitating dose adjustments or alternatives like . Nonstimulant options, including alpha-2 agonists (e.g., ), may serve as first-line for hyperactivity with fewer paradoxical effects. Overall, decisions should prioritize individualized risk-benefit assessments, with periodic trials off medication to evaluate ongoing need, given the absence of curative options and potential for iatrogenic harms.

Family and Supportive Strategies

Parent training programs represent a core evidence-based strategy for families of children with pervasive developmental disorders (PDD), enabling caregivers to implement behavioral interventions at home that complement professional therapies. Systematic reviews indicate these programs moderately reduce core symptoms in children, with standardized mean differences of -0.51 for overall symptoms, alongside improvements in parental and competence. For instance, parent-mediated interventions (PMIs), where trained caregivers deliver structured communication or training, yield significant gains in child adaptive behaviors and family functioning, particularly when initiated early. Such training often focuses on techniques like (ABA) principles adapted for home use, including positive reinforcement and prompting to address repetitive behaviors or social deficits characteristic of PDD. Meta-analyses confirm these approaches decrease disruptive behaviors in children with autism spectrum disorders (encompassing PDD subtypes), with effect sizes indicating sustained benefits up to 12 months post-intervention. Programs tailored to recent diagnoses, delivered within six months of evaluation, further enhance parenting while mitigating , as evidenced by randomized controlled trials. Supportive strategies extend beyond to include family-centered and peer networks, which normalize challenges and foster . Evidence from systematic reviews highlights that clinician-led parent support groups improve psychological by addressing and promoting shared problem-solving, though outcomes vary by intervention intensity. For diverse families, adaptations incorporating in —such as community-based —have demonstrated feasibility and , leading to better adherence and child progress. Respite care and stress-reduction techniques, like integrated into family routines, serve as adjuncts to prevent caregiver burnout, with qualitative data from studies underscoring their role in sustaining long-term engagement. Overall, these strategies emphasize empirical validation over anecdotal , prioritizing interventions with demonstrated causal links to improved family dynamics and child developmental trajectories rather than unproven alternatives.

Controversies and Debates

Impact of DSM-5 Changes

The , published in May 2013, eliminated the broad category of pervasive developmental disorders (PDD) from DSM-IV, which had encompassed autistic disorder, Asperger's disorder, PDD not otherwise specified (PDD-NOS), Rett's disorder, and , replacing them with a single diagnosis of (ASD) characterized by deficits in social communication and social interaction combined with restricted, repetitive patterns of behavior, interests, or activities, present from early development. This restructuring aimed to enhance diagnostic validity and reliability by unifying heterogeneous conditions under a spectrum model with severity levels and specifiers for intellectual impairment, language impairment, and associated medical/genetic conditions, but it removed distinct labels like Asperger's syndrome, which had required no clinically significant delay in language or . Empirical studies comparing DSM-IV PDD diagnoses to ASD criteria have shown that approximately 60-63% of individuals previously classified under PDD retain an diagnosis, with higher concordance for autistic disorder (around 78%) but lower for PDD-NOS (57-59%), indicating that milder or subthreshold cases, particularly those without repetitive behaviors, are most likely to lose diagnostic eligibility. Prevalence estimates for are projected to decrease under relative to DSM-IV-TR, potentially by 10-30%, especially among individuals with average or above-average IQ who previously received PDD-NOS or Asperger's diagnoses, as the new criteria mandate symptoms across both core domains rather than allowing diagnosis based on social impairments alone. This shift has raised concerns about underdiagnosis in borderline cases, though clinical practices and broadened awareness have mitigated observed drops in some populations. The removal of Asperger's as a separate diagnosis has prompted identity-related challenges for some adults, who report a sense of loss tied to the label's association with preserved verbal abilities and higher functioning, influencing self-perception and community affiliations despite DSM-5's provision for noting prior diagnoses in records. Access to services remains a point of contention, as individuals no longer meeting ASD criteria may face eligibility barriers for educational, therapeutic, or insurance supports previously justified under PDD-NOS, although grandfathering of pre-2013 diagnoses and the introduction of social (pragmatic) communication disorder as an alternative have partially addressed gaps. Overall, while DSM-5 changes have improved consistency in severe cases, they have sparked debates on whether the spectrum model overlooks phenotypic variability essential for tailored interventions and research.

Neurodiversity Movement Critiques

Critics of the neurodiversity movement argue that it disproportionately represents the views of high-functioning individuals on the , sidelining those with profound impairments characteristic of many pervasive developmental disorders. The movement, which frames as a natural neurological variation rather than a disorder requiring remediation, is said to be driven primarily by verbally fluent, independently living autistics who can advocate online, excluding nonverbal or low-IQ individuals who comprise a significant portion of cases. For instance, parents of children with severe report feeling marginalized, as the emphasizes over interventions to address debilitating symptoms like self-injurious behavior or lack of communication. A core contention is the movement's opposition to evidence-based treatments such as (ABA), which neurodiversity proponents often label as coercive or akin to , aiming to suppress autistic traits rather than accommodate differences. This stance is critiqued for overlooking data on ABA's effectiveness in reducing maladaptive behaviors and fostering functional skills in severely affected individuals, where up to 40% of autistic children remain nonverbal and 37.9% exhibit (IQ below 70). Critics, including clinicians and some autistics with higher support needs, contend that rejecting such therapies prioritizes ideological purity over empirical outcomes, potentially prolonging suffering from comorbidities like or , which affect a substantial minority of pervasive developmental disorder cases. Furthermore, detractors highlight the paradigm's minimization of autism's pathological aspects, such as neurological abnormalities in and genetic variants linked to cognitive deficits, in favor of a "mere difference" narrative that downplays causal impairments. While acknowledging the movement's role in reducing for milder presentations, analyses note its failure to grapple with the reality that pervasive developmental disorders often involve intractable challenges not resolvable through societal accommodation alone, as evidenced by lifelong dependency in over one-third of cases. This selective focus is seen as ideologically driven, potentially influenced by biases that undervalue medical models validated by longitudinal studies on .

Debates on Prevalence Increases

The reported prevalence of , the primary condition under the historical umbrella of pervasive developmental disorders, has increased markedly since the 1990s. Centers for Disease Control and Prevention (CDC) surveillance data indicate that ASD prevalence among U.S. children aged 8 years rose from 6.7 per 1,000 in 2000 to 27.6 per 1,000 by 2020, reaching approximately 32 per 1,000 (1 in 31) by 2022 based on the Autism and Developmental Disabilities Monitoring (ADDM) Network. Globally, systematic reviews show pooled prevalence escalating from 0.25% in studies from 1994–1999 to 0.99% by 2019–2021. Central to debates is whether this reflects a true rise in incidence driven by causal factors or primarily methodological artifacts. The dominant academic explanation attributes the surge to diagnostic substitution (e.g., reclassifying cases previously labeled as or language disorders), broadened criteria in the (effective 2013, which subsumed Asperger's syndrome and pervasive developmental disorder-not otherwise specified into ), enhanced screening, and reduced stigma leading to more identifications, including in adults and milder cases. Peer-reviewed analyses, such as those tracking Danish and Western Australian cohorts, correlate sharp prevalence jumps with policy-driven diagnostic expansions, with stabilization post-adjustment suggesting no epidemic beyond ascertainment improvements. This view prevails in institutions like the CDC and major journals, potentially influenced by systemic biases favoring non-alarmist interpretations that avoid implicating environmental or societal causal chains. Opposing arguments posit a substantive epidemiological increase persisting after diagnostic controls, evidenced by elevated rates in pre-DSM-5 birth cohorts and disparities between (peaking at 30.3 per 1,000 for ages 5–8 in 2022) and prevalence, implying incomplete historical underdiagnosis. Proponents cite empirical correlates like rising advanced parental age (a documented , with odds ratios increasing 1.5–2-fold per decade delay) and prenatal environmental exposures (e.g., linked to 10–20% higher ASD odds in meta-analyses), arguing that genetic alone (estimated 50–90%) cannot explain rapid multigenerational shifts without gene-environment interactions. While vaccines and certain toxins lack causal support, the dismissal of any true rise overlooks causal realism in population-level trends, as critiqued in reviews noting unadjusted residuals in longitudinal data. No exists, but over-reliance on diagnostic explanations in left-leaning academic circles may underweight verifiable non-genetic contributors to prioritize narrative stability.

Epidemiology and Prognosis

Prevalence and Demographics

The prevalence of pervasive developmental disorders (PDDs), which encompassed conditions such as autistic disorder, Asperger's syndrome, and PDD-not otherwise specified prior to the reclassification in 2013, was estimated at 60-70 per 10,000 children in epidemiological surveys conducted through the early . Following the merger of these categories into spectrum disorder (), U.S. Centers for Disease Control and Prevention (CDC) surveillance data from 2022 indicate a prevalence of 1 in 31 (3.2%) among 8-year-old children, representing an increase from prior estimates of 1 in 36 (2.8%) based on 2020 data. Globally, the estimates prevalence at approximately 1 in 127 individuals as of 2021, though this figure reflects averages across diverse diagnostic practices and may underestimate due to underdiagnosis in low-resource settings. Demographically, PDDs and show a marked predominance, with a -to-female consistently reported at around 4:1 in population-based studies, though some analyses adjusting for diagnostic biases suggest a closer to 3:1. This disparity is evident across age groups, with CDC data confirming is 3.4 times more prevalent in boys than girls among 8-year-olds. estimates have historically been higher in higher-income countries with robust screening, but recent U.S. trends show narrowing racial/ethnic disparities, with identification rates rising among , , and Asian/ children relative to White children, potentially reflecting improved access to evaluation rather than inherent differences. typically occurs in , with median age around 4-5 years in surveillance sites, though delays persist in underserved demographics.

Long-Term Outcomes and Comorbidities

A and of long-term outcomes in individuals with autistic disorders, encompassing pervasive developmental disorders, reported that 47.7% (95% CI: 36.6–59.0%) experienced poor outcomes, 31.1% (95% CI: 23.2–40.4%) fair outcomes, and only 19.7% (95% CI: 14.2–26.6%) good outcomes, with childhood subtype predicting poorer . Longitudinal studies consistently indicate suboptimal adult functioning for 50–60% of individuals, including persistent deficits in , adaptive skills, and daily living despite stability or slight improvements in cognitive scores and core symptoms. Employment outcomes remain particularly poor, with high rates persisting into adulthood; for instance, cohort studies of adolescents transitioning to adults show most fail to achieve competitive or sustained , often relying on supported models or remaining unemployed due to social and executive functioning challenges. is similarly limited, as functional skills for and community participation lag, with many requiring ongoing family or institutional support well into midlife. Recent analyses highlight no elevated risk of cognitive decline or in autistic adults without , though overall quality of life metrics, such as relationship formation and financial stability, trail neurotypical peers. Comorbidities are prevalent, affecting up to 70% of individuals with , including at least one psychiatric disorder, which compounds functional impairments. Neurodevelopmental conditions like attention-deficit/hyperactivity disorder (ADHD) co-occur in approximately 56% of cases, while anxiety disorders affect around 22%, mood disorders 8%, and rates have been estimated at 50–70% in earlier cohorts, though recent data suggest variability by diagnostic criteria. Obsessive-compulsive disorder overlaps in over 11% of pediatric and adolescent cases, often exacerbating repetitive behaviors inherent to . Medical comorbidities, such as (prevalence 5–40% depending on ID severity) and gastrointestinal issues, further influence prognosis but are less universally tied to core developmental trajectories. These co-occurring conditions necessitate integrated management, as untreated comorbidities correlate with worse long-term adaptive outcomes.

References

  1. [1]
    Pervasive Developmental Disorders and Autism Spectrum Disorders
    Pervasive developmental disorders are a condition characterized by a clinical triad of impairment in social interactions; impairment in communications; and a ...
  2. [2]
    Table 5, DSM-IV Pervasive Developmental Disorder Not Otherwise ...
    Severe and pervasive impairment in the development of reciprocal social interaction or verbal and nonverbal communication skills, or when stereotyped behavior, ...
  3. [3]
    How to deal with the transition from Pervasive Developmental ...
    Dec 19, 2011 · PERVASIVE DEVELOPMENTAL DISORDERS (PDD) consist of five subtypes (Autistic Disorder, Rett's Disorder, Childhood Disintegrative Disorder, ...
  4. [4]
    Autism Spectrum Disorders: Etiology and Pathology - NCBI - NIH
    The cause of ASD is unknown, but several genetic and non-genetic risk factors have been characterized that, alone or in combination, are implicated in the ...Abstract · INTRODUCTION · CLINICAL FEATURES · ETIOLOGY
  5. [5]
    Pervasive developmental disorders. Etiological, diagnostic and ...
    Etiological considerations. Etiologically, PDDs are heterogeneous. There is converging evidence suggesting the tremendous significance of biological factors ...
  6. [6]
    Application of DSM-5 criteria for autism spectrum disorder ... - PubMed
    Conclusions: These results suggest that most children with DSM-IV PDD diagnoses would remain eligible for an ASD diagnosis under the proposed DSM-5 criteria.
  7. [7]
    Diagnostic Criteria for Autism Spectrum Disorder in the DSM-5
    Jun 9, 2020 · The Pervasive Development Disorder category no longer appears in DSM-5 , and Autistic disorder , Asperger Syndrome , and PDD-NOS have now been ...
  8. [8]
    A Comparison of DSM-IV Pervasive Developmental Disorder and ...
    The present study indicates that more than 90% of individuals with a DSM-IV PDD diagnosis will have a DSM-5 ASD or SCD diagnosis. Those who no longer ...
  9. [9]
    [PDF] DSM-5 ASD Factsheet - Autism Spectrum Disorder - State of Michigan
    Anyone diagnosed with one of the four pervasive developmental disorders (PDD) from DSM-IV should still meet the criteria for ASD in DSM-5 or another, more ...<|separator|>
  10. [10]
    Pervasive Developmental Disorder (PDD) - Cleveland Clinic
    now known as autism spectrum disorder — are a group of developmental delays that affect social and ...
  11. [11]
    A Genetic Etiology of Pervasive Developmental Disorder Guides ...
    However, a thorough medical, neuropsychological, and genetic evaluation revealed a primary etiology for most of the symptoms and enabled the authors to devise a ...
  12. [12]
    Reassesment of pervasive developmental disorder-not otherwise ...
    While they are classified as “Pervasive Developmental Disorders (PDD)” in DSM-4-TR, DSM-5 defined a single category “Autism Spectrum Disorder”. With this ...
  13. [13]
    Pervasive Developmental Disorder - an overview - ScienceDirect.com
    Pervasive developmental disorders (PDDs) are neurodevelopmental disorders that were proposed initially in the Diagnostic and Statistical Manual of Mental ...
  14. [14]
    Pervasive Developmental Disorder - Not Otherwise Specified (PDD ...
    PDD-NOS is characterized by delays in the development of socialization and communication skills. Parents may notice associated behaviors as early as infancy.
  15. [15]
    The Diagnosis of “Pervasive Developmental Disorder Not Otherwise ...
    This disorder has historically been used to describe individuals who did not fully meet the specific criteria for autism, Asperger's syndrome, schizophrenia, ...
  16. [16]
    Pervasive developmental disorder: Definition and signs
    Oct 17, 2022 · PDD-NOS is a subtype of autism, a developmental disorder that affects development milestones related to things such as communication and social skills.Definition · Diagnosis · Treatment · Causes
  17. [17]
  18. [18]
    Investigating the borders of autism spectrum disorder - Frontiers
    Cross-sectional and longitudinal studies comparing PDD-NOS and AD showed that PDD-NOS corresponds to milder form of autism with less impact and less associated ...
  19. [19]
    Just the Facts: The DSM-5 and Autism Spectrum Disorder
    The DSM-5 will now use the overarching term Autism Spectrum Disorder and allow clinicians to indicate levels of severity. This new change reflects the idea that ...
  20. [20]
    Is Long-Term Prognosis for Pervasive Developmental Disorder Not ...
    The overall adult outcome in both AD and PDD NOS groups was poor, with excessively increased disability rates in both groups relative to the general population, ...
  21. [21]
    implications for young children and their families - PubMed
    The DSM-5 deletes Asperger's Disorder and PDD-NOS as diagnostic entities. ... Changing the current diagnosis of PDD-NOS to a "Social Communication Disorder" ...
  22. [22]
    The changing faces of autism - PubMed Central - NIH
    Jul 28, 2022 · The common understanding of autism spectrum disorders (ASD) has gone through a number of permutations since the first description in 1943.
  23. [23]
    The Diagnosis of Autism: From Kanner to DSM-III to DSM-5 ... - NIH
    In 1979, before autism appeared as a category in DSM, a Medline search revealed that there were approximately 128 papers on the topic. By 1985, there were 335 ...
  24. [24]
    The evolution of 'autism' as a diagnosis, explained | The Transmitter
    May 9, 2018 · The DSM-III was revised in 1987, significantly altering the autism criteria. It broadened the concept of autism by adding a diagnosis at the ...
  25. [25]
  26. [26]
    (PDF) Pervasive developmental disorders: from DSM-III to DSM-III-R
    Aug 7, 2025 · In DSM-III, pervasive developmental disorder is divided into two major categories: infantile autism and childhood onset pervasive developmental ...
  27. [27]
    Pervasive developmental disorders: from DSM-III to DSM-III-R
    ... Pervasive Developmental Disorder Not Otherwise Specified were decided and gives the reasons for the changes from DSM-III (APA, 1980) categories and criteria.
  28. [28]
    Pervasive developmental disorders: From DSM-III to DSM-III-R
    The present paper provides a brief history of the development of the DSM-II-R (American Psychiatric Association [APA], 1987) section on Pervasive Developme.Missing: evolution | Show results with:evolution
  29. [29]
    Moving towards ICD-11 and DSM-V: Concept and evolution of ... - NIH
    We have come a long way till ICD-10 and DSM-IV, but there are shortcomings. With advances in genetics and neurobiology in the future, classification of ...
  30. [30]
    Autism in DSM-5: progress and challenges
    May 15, 2013 · A single disorder and a subthreshold category were described (the name of the latter was changed from atypical PDD to pervasive developmental ...
  31. [31]
    Pervasive Developmental Disorder - an overview - ScienceDirect.com
    Currently, in the DSM-IV-TR, the pervasive developmental disorder category includes autistic disorder, Asperger disorder, pervasive developmental disorder not ...Missing: subtypes | Show results with:subtypes
  32. [32]
    Glossary of DSM-IV Criteria Pervasive Developmental Disorders ...
    Mar 13, 2014 · B. Delays or abnormal functioning in at least one of the following areas, with onset prior to age 3 years: (1) social interaction, (2) language ...
  33. [33]
    DSM IV Criteria For Diagnosing Autistic Disorder*
    1. Qualitative impairment in social interaction, as manifested by at least two of the following: a. marked impairment in the use of multiple nonverbal ...
  34. [34]
    Asessment Methods for Young Children With Possible Autism
    The DSM-IV divides the general category of pervasive development disorders into several subcategories including: (1) autistic disorder, (2) pervasive ...Missing: subtypes | Show results with:subtypes<|separator|>
  35. [35]
    DSM-IV – Diagnostic Classifications
    Pervasive Development Disorders (PDD). The term “PDD” is widely used by professionals to refer to children with autism and related disorders; however, ...
  36. [36]
    DSM-5 and autism spectrum disorders (ASDs) - PubMed Central - NIH
    May 15, 2013 · DSM-5 can improve sample characterization and provide opportunities for researchers to identify possible subtypes within ASD.
  37. [37]
    Autism diagnostic criteria: DSM-5
    Read the full text for the diagnostic criteria of autism spectrum disorder (ASD) from the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).
  38. [38]
    Update on diagnostic classification in autism - PMC - NIH
    Childhood-onset pervasive developmental disorder (PDD) and atypical PDD were also introduced in DSM-III. In 1987, DSM-III-R [8] expanded the menu of ...
  39. [39]
    Application of DSM-5 Criteria for Autism Spectrum Disorder to Three ...
    Oct 1, 2012 · This study evaluated the proposed DSM-5 criteria for the single diagnostic category of autism spectrum disorder in children with DSM-IV ...Missing: consolidation | Show results with:consolidation
  40. [40]
    The Diagnosis of Autism: From Kanner to DSM-III to DSM-5 and ...
    Feb 24, 2021 · Throughout this review, we will discuss the evolution of autism as a diagnostic concept as well as highlight important areas of work on the condition.
  41. [41]
    Potential Impact of DSM-5 Criteria on Autism Spectrum Disorder ...
    Autism spectrum disorder prevalence estimates will likely be lower under DSM-5 than under DSM-IV-TR diagnostic criteria.
  42. [42]
    The Impact of DSM-5 on the Diagnosis of Autism Spectrum Disorder
    Dec 5, 2020 · Using the DSM-5 criteria, the loss of ASD diagnosis was greater for those with an average IQ or higher. Only 36% of participants with an IQ ...
  43. [43]
    DSM-5 Impact on Services | CHOP Research Institute
    Aug 20, 2020 · Previous diagnoses of Asperger disorder and PDD-NOS have been grandfathered into the new ASD diagnosis in DSM-5 . Individuals with a history ...Missing: implications | Show results with:implications
  44. [44]
    Autism in DSM-5: progress and challenges - PMC - PubMed Central
    May 15, 2013 · A second disorder, social (pragmatic) communication disorder, was added, although its relation to the autism spectrum disorders (ASD) remains ...
  45. [45]
    Editorial: DSM‐5 and autism spectrum disorders – two decades of ...
    Jul 16, 2012 · The rationale for combining the individual PDD diagnoses into a single category of Autism Spectrum Disorder (ASD), when we hear so much about ...
  46. [46]
    Autism spectrum disorders - PMC - NIH
    Communication impairment. Delayed or absent speech. Deficient nonverbal communication e.g. lack pointing, difficulty following a point ; Social impairment. Lack ...
  47. [47]
    TARGETING SOCIAL SKILLS DEFICITS IN AN ADOLESCENT WITH ...
    In the current study, an adolescent with PDD displayed inappropriate social behavior (inappropriate comments, social withdrawal, and touching others without ...
  48. [48]
    Toward Specifying Pervasive Developmental Disorder ... - PubMed
    Feb 4, 2011 · Compared to AD and AsD, they had comparably severe but more circumscribed social communication difficulties, with fewer non-social features of ...
  49. [49]
    Restricted and Repetitive Behaviors in Toddlers and Preschoolers ...
    We found that RRBs occurred more frequently and were more severe in young children with autism and PDD-NOS diagnoses than children in other groups.
  50. [50]
    Repetitive Behavior and Restricted Interests in Young Children with ...
    Restricted, repetitive and stereotyped patterns of behavior, interests and activities (RRBs) are among the core symptoms of autism spectrum disorders (ASD).
  51. [51]
    Subcategories of restricted and repetitive behaviors in children ... - NIH
    Research suggests that restricted and repetitive behaviors (RRBs) can be subdivided into repetitive sensory motor (RSM) and insistence on Sameness (IS) ...
  52. [52]
    Biopsychological correlates of repetitive and restricted behaviors in ...
    Sep 2, 2021 · RRBs can be divided into lower‐level behaviors (motor, sensory, and object‐manipulation behaviors) and higher‐level behaviors (restrictive ...
  53. [53]
    Patterns of Restricted and Repetitive Behaviors in Autism Spectrum ...
    May 21, 2021 · The repetitive use of objects, repetitive activities or ritualism, and repetitive speech are considered repetitive behaviors [2,3]. Numerous ...
  54. [54]
    Restricted and repetitive behavior in children with autism during the ...
    In general, RRBs are a continuum of behaviors that may include repetitive motor movements like hand flapping, preoccupation with parts, and circumscribed or ...
  55. [55]
    Developmental Trajectories of Restricted and Repetitive Behaviors ...
    This study examined how restricted and repetitive behaviors and interests (RRBs) developed over time in a sample of children with Autism Spectrum Disorders ...
  56. [56]
    Reduced Behavioral Flexibility in Autism Spectrum Disorders - NIH
    Restricted and repetitive behaviors in ASD are associated with neurocognitive deficits in flexible choice behavior.<|control11|><|separator|>
  57. [57]
    Repetitive Restricted Behaviors in Autism Spectrum Disorder
    RRBs are behavioral patterns characterized by repetition, inflexibility, invariance, inappropriateness, and frequent lack of obvious function or specific ...Abstract · Introduction · Mechanism of Repetitive... · Treatment and Intervention of...
  58. [58]
    Restricted and repetitive behaviors in autism spectrum disorders
    Restricted and repetitive behaviors (RRBs) are a core feature of autism spectrum disorders. They constitute a major barrier to learning and social adaptation.
  59. [59]
    Restricted and repetitive behaviors in autism spectrum disorders
    Restricted and repetitive behaviors (RRBs) are hallmark symptoms of autism spectrum disorders (ASDs); however, it has proven difficult to understand the ...
  60. [60]
    [PDF] Prevalence and Characteristics of Autism Spectrum Disorder Among ...
    Apr 12, 2019 · Autism spectrum disorder (ASD) is a developmental disability marked by social and communication impairments, as well as restricted interests and ...
  61. [61]
    Clinical heterogeneity among people with high functioning autism ...
    Feb 20, 2008 · The clinical heterogeneity observed in those with an autistic spectrum condition at the higher-IQ end of the spectrum is associated with a gradient in the ...
  62. [62]
    Detecting Subgroups in Children Diagnosed with Pervasive ... - NIH
    These findings suggested that a majority of children with PDD-NOS presented with difficulties in communication skills in addition to deficits in reciprocal ...
  63. [63]
    Frontiers | Heterogeneity within Autism Spectrum Disorders
    As research progressed, the clinical and neurobiological validity of the categorical distinctions between Autism, Asperger's Syndrome, and PDD-NOS appeared ...
  64. [64]
    ADHD symptom subtypes in children with pervasive developmental ...
    The Combined type had more severe oppositional, aggressive, and PDD symptoms than Inattentive type and were from less advantaged homes than other subtypes.
  65. [65]
    Etiological heterogeneity in autism spectrum disorders: More than ...
    The genetic architecture of ASDs is highly heterogeneous (Abrahams and Geschwind, 2008). About 10%–20% of individuals with an ASD have an identified genetic ...
  66. [66]
    An Overview of Autism Spectrum Disorder, Heterogeneity and ...
    Feb 17, 2017 · The heterogeneity of clinical entities is in part a function of the multiple genes involved, the myriad of environmental factors impacting the ...
  67. [67]
    The Heritability of Autism Spectrum Disorder - JAMA Network
    Sep 26, 2017 · Twin studies estimate the proportion of the phenotype variance due to genetic factors (heritability) to be about 90%.
  68. [68]
    Heritability of Autism - an overview | ScienceDirect Topics
    Early twin studies evaluating the heritability of autism showed high disease concordance rates in monozygotic twins (70–90%) and concordance rates of 6–10% in ...
  69. [69]
    Genetic Heritability and Shared Environmental Factors Among Twin ...
    The results suggest that environmental factors common to twins explain about 55% of the liability to autism. Although genetic factors also play an important ...
  70. [70]
    Common polygenic risk for autism spectrum disorder (ASD) is ...
    Mar 10, 2015 · ASD polygenic scores explain <0.5% of the variance in cognitive test scores in all cases (Figure 1). A positive relationship between ASD ...
  71. [71]
    Polygenic scores for autism are associated with reduced neurite ...
    Feb 24, 2025 · Polygenic scores for autism are associated with reduced neurite density in adults and children from the general population | Molecular ...
  72. [72]
    Integrating de novo and inherited variants in 42,607 autism ... - Nature
    Aug 18, 2022 · Overall, people with LoF mutations in de novo genes have an average of 13–16 points lower predicted IQ than individuals with LoF mutations in ...
  73. [73]
    Autism spectrum disorder: MedlinePlus Genetics
    Oct 21, 2021 · Learn more about the genes associated with Autism spectrum disorder · ADNP · ANK2 · ARID1B · ASH1L · CHD2 · CHD8 · CTNND2 · DYRK1A ...
  74. [74]
    New genetic analyses provide estimates of de novo mutations in low
    Apr 18, 2022 · Preliminary results suggest that de novo mutations contribute to 52–67 percent of ASD in low-risk families, but only 9–11 percent in high-risk families.
  75. [75]
    Damaging de novo mutations diminish motor skills in ... - PNAS
    In individuals with autism spectrum disorder (ASD), de novo mutations have previously been shown to be significantly correlated with lower IQ but not with the ...
  76. [76]
    The contributions of rare inherited and polygenic risk to ASD in ... - NIH
    Jul 28, 2023 · We also find that ASD polygenic score (PGS) is overtransmitted from nonautistic parents to autistic children who also harbor rare inherited ...
  77. [77]
    De novo Mutations (DNMs) in Autism Spectrum Disorder (ASD)
    Here, we review different aspects of the DNMs associated with ASD, including their functional annotation and classification.DNMs in ASD Genetics · Bioinformatics Approaches... · Caveats and Future...
  78. [78]
    The Association Between Parental Age and Autism-Related ... - NIH
    Advanced parental age is one of the most consistently identified perinatal risk factors for autism spectrum disorder (ASD), a complex neurodevelopmental ...
  79. [79]
    Autism risk associated with parental age and with increasing ...
    Jun 9, 2015 · Advancing paternal and maternal age have both been associated with risk for autism spectrum disorders (ASD). However, the shape of the ...
  80. [80]
    Association of Grandparental and Parental Age at Childbirth With ...
    Apr 15, 2020 · Advanced paternal or maternal age over 30 years was monotonically associated with increased ASD risk, with odds ratios (ORs) of 1.56 (95% CI, ...
  81. [81]
    Prenatal environmental risk factors for autism spectrum disorder and ...
    Sep 16, 2024 · Infection during pregnancy, gestational diabetes, and maternal obesity are established risk factors for ASD. Emerging areas of research include ...
  82. [82]
    Prenatal environmental risk factors for autism spectrum disorder and ...
    Sep 16, 2024 · Several epidemiological studies have shown that pre-pregnancy obesity increases the odds of ASD in children by 1.3–2.0-fold [7]. Additionally, ...
  83. [83]
    In Utero Valproate Exposure and Autism: Long Suspected ... - NIH
    Maternal use of valproate during pregnancy was associated with a significantly increased risk of autism spectrum disorder and childhood autism in the offspring.
  84. [84]
  85. [85]
    Autism Spectrum Disorder - StatPearls - NCBI Bookshelf
    Jan 17, 2025 · Prenatal exposure to phthalates, air pollutants, and heavy metals such as lead and mercury may increase the likelihood of ASD. Pesticides may ...
  86. [86]
    Environmental pollutants as risk factors for autism spectrum disorders
    Sep 3, 2024 · This study found positive associations nitrogen dioxide, copper, mono-3-carboxypropyl phthalate, monobutyl phthalate, and PCB 138, and the development of ASD.
  87. [87]
    Vaccines are not associated with autism: an evidence-based meta ...
    Jun 17, 2014 · There has been enormous debate regarding the possibility of a link between childhood vaccinations and the subsequent development of autism.
  88. [88]
    Autism and Vaccines - CDC
    Dec 30, 2024 · No links have been found between any vaccine ingredients and ASD. Vaccines do not cause autism. Autism spectrum disorder (ASD) is a ...
  89. [89]
    The Evidence on Vaccines and Autism | Johns Hopkins
    Mar 19, 2025 · In 1971, the FDA approved the measles-mumps-rubella (MMR) vaccine, which combined three vaccines that had been approved previously—in 1963, ...
  90. [90]
    Early Infantile Autism and the Refrigerator Mother Theory (1943-1970)
    Aug 19, 2014 · In this article, Katz credited Rimland for rejecting refrigerator mother theory as a myth and for encouraging biological research into autism, ...<|separator|>
  91. [91]
    The Heritability of Autism Spectrum Disorder - PMC - NIH
    In a previous study, ASD heritability was estimated to be 0.50, and shared familial environmental influences to be 0.04. To define presence or absence of ASD, ...
  92. [92]
    Association of Genetic and Environmental Factors With Autism in a 5 ...
    Jul 17, 2019 · Based on population data from 5 countries, the heritability of ASD was estimated to be approximately 80%, indicating that the variation in ASD ...
  93. [93]
    What do we know about genes and environmental factors in autism?
    Jun 25, 2025 · "In the case of autism, heritability is estimated at around 80–90 per cent. This doesn't necessarily mean that the diagnosis is always inherited ...
  94. [94]
    Efficacy of Interventions Based on Applied Behavior Analysis ... - NIH
    To systematically evaluate evidence for the use of interventions based on appied behavior analysis (ABA) to manage various symptoms of children with autism ...
  95. [95]
    A Meta-Analysis of Applied Behavior Analysis-Based Interventions ...
    May 16, 2025 · This meta-analysis examined the effectiveness of Applied Behavior Analysis-based (ABA) interventions, including Naturalistic Developmental Behavioral ...
  96. [96]
    The effectiveness of applied behavior analytic interventions for ...
    The findings indicated that ABA programs are moderately to highly effective bringing significant benefits for children with ASD in the aforementioned areas.
  97. [97]
    Early intensive behavioral intervention (EIBI) for young children with ...
    EIBI is a treatment based on the principles of applied behavior analysis. Delivered for multiple years at an intensity of 20 to 40 hours per week.
  98. [98]
    A follow-up study of early intensive behavioral intervention program ...
    Jan 2, 2023 · We examined the sustained effects of early intensive behavioral intervention (EIBI) on 66 children with autism spectrum disorder who participated in the Future ...
  99. [99]
    Educational Interventions for Children and Youth with Autism: A 40 ...
    The purpose of this commentary is to describe school-based and school-relevant interventions and instructional approaches for children and youth with autism.
  100. [100]
    The TEACCH program for children and adults with autism: A meta ...
    Our results indicated that TEACCH effects on perceptual, motor, verbal and cognitive skills were of small magnitude in the meta-analyzed studies.
  101. [101]
    Effects of TEACCH on social functioning in individuals with autism ...
    Jul 24, 2025 · The main outcome measures were social, cognitive performance, fine motor, communication, daily living, imitation, and cognitive verbal skills.
  102. [102]
    Evidence-Based Practices for Children, Youth, and Young Adults ...
    This systematic review describes a set of practices that have evidence of positive effects with autistic children and youth.
  103. [103]
    Determining Associations Between Intervention Amount and ...
    Jun 24, 2024 · This meta-analysis investigates if the amount of intervention provided to young autistic children is associated with improved child ...
  104. [104]
    Developmental Relationship-Based Interventions for Autistic Children
    Dec 24, 2024 · Four strategies consistently used in DRBI are: Social Play, Sensitive Responding, Following the Child's Lead, and Presenting Challenges. We also ...<|separator|>
  105. [105]
    Autism intervention meta-analysis of early childhood studies (Project ...
    Nov 14, 2023 · To summarize the breadth and quality of evidence supporting commonly recommended early childhood autism interventions and their estimated effects on ...
  106. [106]
    [PDF] Optimal Use of ABA for Autism in Children and Young Adults
    Sep 17, 2024 · Interventions based on early intensive applied behaviour analysis for autistic children: a systematic review and cost-effectiveness analysis.
  107. [107]
    Autism Spectrum Disorder Treatment & Management
    Oct 15, 2025 · No pharmacologic agent is effective in the treatment of the core behavioral manifestations of ASD, but drugs may be effective in treating ...
  108. [108]
    Pharmacological treatment in autism: a proposal for guidelines on ...
    Jan 7, 2025 · Currently, only two drugs have been approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the ASD population: ...
  109. [109]
    An Update on Psychopharmacological Treatment of Autism ...
    Apr 15, 2024 · An Update on Psychopharmacological Treatment of Autism Spectrum Disorder ... Practitioner Review: Pharmacological treatment of attention ...
  110. [110]
    Aripiprazole for irritability associated with autistic disorder in children ...
    Currently, the only two FDA-approved medications to treat irritability in autistic individuals are risperidone and aripiprazole.
  111. [111]
    U.S. Food and Drug Administration Approves ABILIFY ...
    Nov 20, 2009 · ABILIFY (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years.
  112. [112]
    Risperidone and aripiprazole for autism spectrum disorder in children
    Both aripiprazole and risperidone were effective for reducing autism symptoms severity, repetitive behaviours, inappropriate language, social withdrawal and ...
  113. [113]
    06. Treatment of Irritability in ASD: Risperidone and Aripiprazole
    Feb 1, 2023 · Risperidone and aripiprazole are FDA approved for treating irritability in children and adolescents with ASD. Metabolic side effects are ...
  114. [114]
    Olanzapine, risperidone, and aripiprazole use in children and ...
    The two currently FDA-approved products for the irritability associated with autism include risperidone and aripiprazole. Multiple studies and clinical ...
  115. [115]
    Efficacy and safety of risperidone and aripiprazole in reducing ...
    Both risperidone and aripiprazole are effective in reducing irritability severity in children with autism spectrum disorder (ASD).
  116. [116]
    Pharmacotherapy of restricted/repetitive behavior in autism ...
    Mar 12, 2020 · The results offer further evidence suggesting that SSRIs have little or no effect on treatment of RRBs in children and adults patients with ASD ...
  117. [117]
    Treating Repetitive Behavior in ASD: Citalopram Not Effective
    Nov 1, 2009 · The authors conclude that their results do not support the use of citalopram for the treatment of repetitive behavior in children and adolescents with ASDs.
  118. [118]
    Antidepressants for Restricted and Repetitive Behaviors in Autism ...
    Oct 2, 2024 · One meta-analysis conducted in 2020, showed no significant difference between SSRIs and placebo in treating RRBs in ASD. A previous review did ...
  119. [119]
    Psychostimulants for ADHD-like symptoms in individuals with autism ...
    Jan 9, 2014 · The results of the selected reports suggest that psychostimulants may be effective for ADHD-like symptoms in autism spectrum disorder individuals.
  120. [120]
    The effect of stimulants on irritability in autism comorbid with ADHD
    Jun 6, 2019 · Stimulants usually improve irritability in ADHD. Aripiprazole/methylphenidate combination significantly improves irritability in children with ...
  121. [121]
    [PDF] ADHD in Youth with ASD: Parents' Medication Guide - AACAP
    FIRST-LINE NONSTIMULANT MEDICATIONS Nonstimulant medications are also effective for treating symptoms of ADHD in youth with ASD. These may be used first or ...
  122. [122]
    Pharmacological treatments in autism spectrum disorder: a narrative ...
    Jul 26, 2023 · Aripiprazole and risperidone have shown effectiveness in treating irritability and aggression in ASD, while methylphenidate may be helpful in reducing ...<|separator|>
  123. [123]
    The effectiveness of parent training for children with autism spectrum ...
    Dec 7, 2020 · We carried out a systematic review and meta-analyses to assess effectiveness of parental training for children with autism on their symptoms and parental ...
  124. [124]
    Parent-Mediated Interventions for Children and Adolescents With ...
    Nov 11, 2021 · The objective of this systematic review and meta-analysis was to examine the effect of PMIs compared to no PMI for children with ASD aged 2–17 years.
  125. [125]
    (PDF) A Systematic Review and Meta-analysis of Parent Training for ...
    Aug 7, 2025 · Parent training (PT) has emerged as a promising treatment for disruptive behavior in children with autism spectrum disorder (ASD).<|separator|>
  126. [126]
    The effects of a parent-focused intervention for children with a recent ...
    The aim of the present study was to reduce parenting stress and increase parenting competence for families of children within 6 months of receiving an ASD ...
  127. [127]
    A systematic review of the effectiveness and efficacy of clinician-led ...
    This review systematically considered outcomes in relation to parent-targeted clinician led interventions to support parents' mental health and well-being.
  128. [128]
    Adapting parent-focused interventions for diverse caregivers of ...
    Parent-focused interventions have been designed to provide training and support to caregivers who are essential in achieving positive outcomes for children ...
  129. [129]
    Advances in Supporting Parents in Interventions for Autism ...
    Strategies for supporting caregivers of children with ASD can include mindfulness-based stress reduction programs, tailored interventions for unique family ...
  130. [130]
    [PDF] Evidence-Based Practices for Children, Youth, and Young Adults ...
    To qualify for the review, participants in a study had to be between birth and 22 years of age and identified as having ASD: autism, Asperger syndrome, ...
  131. [131]
    DSM-5 criteria for autism spectrum disorder maximizes diagnostic ...
    Mar 8, 2019 · Agreement between DSM-5 and DSM-IV-TR definitions of ASD were good for autistic disorder (0.78) and moderate for PDD-NOS (0.57 and 0.59).Missing: effects | Show results with:effects
  132. [132]
    Potential impact of DSM-5 criteria on autism spectrum disorder ...
    Autism spectrum disorder prevalence estimates will likely be lower under DSM-5 than under DSM-IV-TR diagnostic criteria.
  133. [133]
    Increasing Prevalence, Changes in Diagnostic Criteria, and ... - NIH
    Relaxed DSM-5 criteria may further improve identification of ASD and decrease societal costs through appropriate early diagnosis and maximizing limited ...
  134. [134]
    Identity in People with an Asperger's Diagnosis After DSM-5 - PubMed
    This Australian study explored the role of disability identity development in responses to the change through semi-structured interviews with 12 adults ...
  135. [135]
    [PDF] Does the DSM-5 Threaten Autism Service Access?
    Feb 24, 2015 · The first is a direct route where a DSM change impacts a policy like insurance coverage that is explicitly tied to a DSM diagnosis. The second ...
  136. [136]
    Autism Spectrum Disorder Versus Autism Spectrum Disorders - NIH
    Evaluations of DSM-5 versus DSM-IV ASD criteria have demonstrated a lower overall prevalence of ASD using DSM-5 criteria, but greater agreement between DSM-IV ...Missing: effects | Show results with:effects
  137. [137]
    Critiques of the Neurodiversity Movement - SpringerLink
    Nov 8, 2019 · Several vocal autistic people and parents have complained that the movement is made up mostly of less impaired individuals who do not represent ...
  138. [138]
    Why the neurodiversity movement has become harmful | Aeon Essays
    Sep 12, 2019 · The movement has good intentions, but it favours the high-functioning and overlooks those who struggle with severe autism.
  139. [139]
    Applied Behavior Analysis and the Abolitionist Neurodiversity Critique
    The neurodiversity movement is analogously committed to a mere-difference account of autism (and potentially of other developmental disabilities as well).
  140. [140]
    Prevalence and Characteristics of Autism Spectrum Disorder Among ...
    Mar 24, 2023 · Among the 4,165 (66.7%) children with ASD with information on cognitive ability, 37.9% were classified as having an intellectual disability.
  141. [141]
    Data and Statistics on Autism Spectrum Disorder - CDC
    May 27, 2025 · Prevalence of ASD. About 1 in 31 (3.2%) children aged 8 years has been identified with ASD according to estimates from CDC's ADDM Network.MMWR · Autism Data Visualization Tool · Autism Prevalence Studies...
  142. [142]
    Prevalence and Early Identification of Autism Spectrum ... - CDC
    Apr 17, 2025 · Conclusion. Autism prevalence among children aged 8 years increased from 2020 to 2022. Prevalence in 2022 continued to vary widely across sites.Missing: debates | Show results with:debates
  143. [143]
  144. [144]
    The global prevalence of autism spectrum disorder: A three-level ...
    Feb 9, 2023 · The global pooled point-prevalence of ASD consistently increased from 0.25% (95% CI = 0.12–0.42) during the period from 1994 to 1999 to 0.99 (95 ...
  145. [145]
    Is There an Autism Epidemic? | Johns Hopkins
    Jun 6, 2025 · There are two main reasons for the increase. The first is the broadened definition of Autism Spectrum Disorder, which means that more people are ...
  146. [146]
    The Real Reason Autism Rates Are Rising - Scientific American
    Apr 17, 2025 · While there are environmental risk factors for autism, such as air pollution, rising rates are mostly attributable to broadened diagnostic ...
  147. [147]
    Three Reasons Not to Believe in an Autism Epidemic - PMC - NIH
    According to some lay groups, the nation is experiencing an autism epidemic—a rapid escalation in the prevalence of autism for unknown reasons.
  148. [148]
    Explaining the Increase in the Prevalence of Autism Spectrum ...
    Nov 3, 2014 · Two studies noted a sharp increase in ASD prevalence coincident with a change in diagnostic criteria in Western Australia and Denmark, although ...
  149. [149]
    Global prevalence of autism: A systematic review update - PMC - NIH
    Mar 3, 2022 · Factors known to account for the rise in prevalence include the increase in community awareness and public health response globally, changes in ...Search Strategy · Results · Case Identification And...
  150. [150]
    Autism is on the rise: what's really behind the increase? - Nature
    Aug 26, 2025 · Some researchers argue that the influence of environmental factors is vanishingly small, and others disagree.
  151. [151]
    Autism Diagnosis Among US Children and Adults, 2011-2022
    Oct 30, 2024 · Hypothesized reasons for prevalence increases include changes to developmental screening practices, diagnosis definitions, policies, and ...Missing: debates | Show results with:debates
  152. [152]
    Evaluating Changes in the Prevalence of the Autism Spectrum ...
    Debates about reasons for increases in ASD prevalence often have been dichotomized into explanations related to factors such as better identification and ...
  153. [153]
    Understanding autism: Causes, diagnosis, and advancing therapies
    Its rising prevalence has made it a critical global public health issue. ASD is believed to arise from a combination of genetic and environmental influences. ...Review · 3. Genetic Factors In Asd... · 3.7. Early Diagnosis Of Asd
  154. [154]
    Autism diagnoses are on the rise – but autism itself may not be - BBC
    May 10, 2025 · But decades of research into autism have shown that its causes are complex – and mostly genetic. ... Autism prevalence is estimated at roughly 1% ...Autism: Understanding my... · The genetic mystery of why...<|separator|>
  155. [155]
    Prevalence and Interpretation of Recent Trends in Rates of ...
    In conclusion, the convergence of estimates around 60 to 70 per 10,000 for all PDDs combined, which translates into 1 child out of 150 suffering from a PDD, is ...
  156. [156]
    Epidemiology of pervasive developmental disorders - PubMed
    This article reviews the results of 43 studies published since 1966 that provided estimates for the prevalence of pervasive developmental disorders (PDDs), ...
  157. [157]
    Autism Prevalence Higher, According to Data from 11 ADDM ... - CDC
    Mar 22, 2023 · One in 36 (2.8%) 8-year-old children have been identified with autism spectrum disorder (ASD), according to an analysis published today in CDC's Morbidity and ...
  158. [158]
    Autism - World Health Organization (WHO)
    Sep 17, 2025 · It is estimated that worldwide in 2021 about 1 in 127 persons had autism (1). This estimate represents an average figure, and reported ...
  159. [159]
    What Is the Male-to-Female Ratio in Autism Spectrum Disorder? A ...
    Of children meeting criteria for ASD, the true male-to-female ratio is not 4:1, as is often assumed; rather, it is closer to 3:1.
  160. [160]
    Autism Spectrum Disorder (ASD) - National Institute of Mental Health
    Prevalence of ASD · Across the CDC surveillance sites, an average of 1 in every 31 (3.2%) 8-year-old children were estimated to have ASD in 2022. · ASD is 3.4 ...
  161. [161]
    New CDC Report Shows Increase in Autism in 2022 with Notable ...
    Apr 17, 2025 · The CDC report, which includes data from 16 study sites across the US including Maryland, found an overall prevalence of autism of 1 in 31 (3.2%) among 8-year- ...
  162. [162]
    A systematic review and meta‐analysis of the long‐term overall ...
    Jan 13, 2016 · An estimated 19.7% (95%CI: 14.2–26.6) had a good outcome, 31.1% (95%CI: 23.2–40.4%) a fair outcome, and 47.7% (95%CI: 36.6–59.0) a poor outcome.
  163. [163]
    A Meta-analysis of Outcome Studies of Autistic Adults
    Nov 17, 2020 · Longitudinal studies have generally reported poor outcomes in adulthood for the majority of individuals (c.50–60%) with autism.
  164. [164]
    A systematic review of longitudinal follow-up studies in adulthood
    Twenty five adult outcome studies of individuals with ASD were identified. · Overall, cognitive scores were stable; adaptive skills and ASD symptoms improved.<|separator|>
  165. [165]
    The long-term outcomes of a cohort of adolescents and adults from ...
    Nov 16, 2019 · In accordance with the literature, the overall outcome was very poor or poor in most cases as overall outcomes for adults with ASD in terms of ...
  166. [166]
    Factors Associated with Sustained Community Employment among ...
    Jul 9, 2017 · Thus, although there are a number of studies demonstrating that adults with ASD and ID are at greater risk for unemployment or less vocational ...
  167. [167]
    Review Outcomes in adolescents and adults with autism
    This paper is a critical review of the current empirical studies that have addressed prognosis in this population in terms of diagnostic severity, cognitive ...
  168. [168]
    Long-term and adult outcomes in autism spectrum disorder - PMC
    Regarding aging in autism, a recent study found no evidence for heightened risk of cognitive decline or dementia in autistic adults without ID. Several groups ...
  169. [169]
    Risk of psychiatric comorbidity with autism spectrum disorder and its ...
    Psychiatric comorbidity in ASD is common. A study (DeFilippis, 2018) stated that 70% of individuals with ASD had at least one comorbid psychiatric disorder, and ...
  170. [170]
    Age of Autism Spectrum Disorder Diagnosis and Comorbidity in ...
    Research has found that 70% of children and adolescents with ASD have a minimum of one comorbid condition with social anxiety being the most reported symptom.
  171. [171]
    Comorbidity in autism spectrum disorders: a sample of 258 cases
    Most common disorders were found to be Attention deficit hyperactivity disorder (ADHD) (56.2%), anxiety disorders (21.7%), mood disorders (8.1%), learning ...
  172. [172]
    Autism spectrum disorder: definition, epidemiology, causes, and ...
    ASD is a neurodevelopmental disorder characterized by deficits in social communication and the presence of restricted interests and repetitive behaviors. Recent ...
  173. [173]
    Prevalence and Correlates of the Concurrence of Autism Spectrum ...
    Our results indicate that ASD and OCD are commonly concurrent disorders among children and adolescents, with a co-occurrence prevalence of over 11.0% for both ...
  174. [174]
    Autism spectrum disorders and psychiatric comorbidities: a narrative ...
    Jul 26, 2023 · The aim of this narrative review is to make an overview of psychiatric comorbidities of ASD, updating prevalence, highlighting symptoms and available ...